Why don’t short-term trials settle the melasma question for topical estrogen?
Because melasma may be a delayed and uncommon reaction, and most of the controlled studies on topical estrogen have only run for about 12 to 20 weeks, or 3 months. In Dr. Ellen Gendler's discussion with us at Alloy, she notes that short trials haven't reported melasma, but that doesn't fully settle the issue because someone could use estrogen much longer and develop pigment changes later.
There are other reasons short trials can't give a final answer. Melasma risk seems to be tied more strongly to much higher systemic estrogen exposure, like pregnancy or birth control pills, than to low dose topical estrogen on the face. On top of that, individual history matters a lot. People who are prone to melasma, especially if they've had it before, may respond differently than people who haven't. That makes it harder for a short study to capture every real-world pattern.
So the short-term data is reassuring, not definitive. For example, in our M4 study, there was no increase in pigmentation over 3 months, which is helpful, but it doesn't prove melasma can never happen.
If you want the clearest explanation, this short video chapter is the most on-point: Melasma and topical estrogen. We also go into it in our article with Dr. Gendler here: Why topical estrogen should be part of your skincare.
This answer was created using the following resources: